Bristol-Myers Squibb Company (BMY) AI Stock Analysis

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets innovative medicines worldwide across hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 indications. Its commercialized products include Revlimid, Eliquis, Opdivo, Pomalyst/Imnovid, Orencia, Sprycel, Yervoy, and Abraxane. The company also advances a development pipeline featuring Reblozyl, Empliciti, Zeposia, Breyanzi, Inrebic, and Onureg. Bristol-Myers Squibb distributes therapies through wholesalers, distributors, pharmacies, hospitals, clinics, retailers, and government agencies.

Between FY2021 and FY2025, Bristol-Myers Squibb posted a 5-year revenue CAGR of 2.5%, moving from $46.38B in FY2021 to $48.20B in FY2025. Annual net income shifted from $6.99B in FY2021 to -$8.95B in FY2024, before recovering to $7.05B in FY2025 alongside a 28.5% operating margin. In FY2025, gross margin stood at 71.1% while R&D expense totaled $9.95B. For the latest quarter ended June 30, 2026, quarterly revenue grew 5.7% year-over-year, while quarterly earnings increased 153.1%. Over the trailing twelve months, total revenue reached $49.19B with a net profit margin of 18.9% and an EPS of $4.54.

As of June 30, 2026, Bristol-Myers Squibb held $11.07B in cash and short-term investments against $43.12B in total debt, resulting in net debt of $32.05B. Total assets stood at $87.63B and shareholders' equity was $22.32B, reflecting a debt-to-equity ratio of 1.93 and a current ratio of 1.53. In FY2025, operating cash flow reached $14.16B and free cash flow was $12.85B, funding $1.31B in capital expenditures and $5.04B in dividends paid, while the 5-year share count fell 7.7%.

At $59.75 per share, Bristol-Myers Squibb carries a market capitalization of $122.05B and an enterprise value of $156.04B. The stock trades at a trailing P/E of 13.2x and a forward P/E of 9.4x, both below the median of its S&P 500 Healthcare peers at 28.9x and 16.6x, respectively. Its enterprise value-to-EBITDA multiple of 9.4x also sits below the peer median of 15.7x. Over the past year, BMY shares returned 43.8%, outperforming the S&P 500 ETF (SPY) return of 16.8%, though its 5-year return of 25.9% trails the S&P 500 return of 83.0%.

Bristol-Myers Squibb pays an annualized forward dividend of $2.52 per share, representing a 4.22% dividend yield supported by a 38.7% payout ratio. The company has paid quarterly dividends for 55 consecutive years, delivering a 5-year annualized dividend growth rate of 1.6%. Its most recent ex-dividend date was October 2, 2026.

Wall Street coverage consists of 6 Strong Buy, 4 Buy, 17 Hold, 0 Sell, and 1 Strong Sell recommendations. The mean price target of $65.62 implies a 9.8% premium to the last close of $59.75. For the current fiscal year ending December 31, 2026, consensus estimates project EPS of $6.62 on revenue of $49.88B. The company beat EPS estimates in each of the last 4 quarters, with next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Bristol-Myers Squibb Company (BMY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BMY income statement, BMY balance sheet, BMY key metrics, BMY analyst forecast, BMY chart. See the BMY stock overview for the latest quote and news.